Pfizer (PFE): FDA approves Tukysa regimen as first-line maintenance for HER2+ breast cancer

The FDA approved Pfizer's Tukysa with trastuzumab and pertuzumab as first-line maintenance for HER2-positive metastatic breast cancer. In the 654-patient HER2CLIMB-05 trial, median PFS was 24.9 vs 16.3 months. Liver enzyme rises were more common.

Sources

• OncLive, FDA approves tucatinib plus trastuzumab and pertuzumab as first-line maintenance
• AJMC, FDA approves tucatinib maintenance for HER2 metastatic breast cancer